Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: Monitoring and treatment algorithm for clinicians

Drug Safety

Volumn 33, Issue 1, 2010, Pages 25-34

  Chroni, Elisabeth ^a   Monastirli, Alexandra ^a   Tsambaos, Dionysios ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETRETIN; ISOTRETINOIN; LITHIUM; TETRACYCLINE;

ABDUCENS NERVE PARALYSIS; ACNE; BRAIN PSEUDOTUMOR; CENTRAL NERVOUS SYSTEM; CLASSIFICATION ALGORITHM; CREATINE KINASE BLOOD LEVEL; DEMYELINATING DISEASE; DIPLOPIA; DRUG CONTRAINDICATION; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EEG ABNORMALITY; EXERCISE; GUILLAIN BARRE SYNDROME; HUMAN; INTRACRANIAL HYPERTENSION; MUSCLE STIFFNESS; MYALGIA; MYOPATHY; NAUSEA; NERVE INJURY; NEUROMUSCULAR DISEASE; OCULOGYRIC CRISIS; OPHTHALMOPLEGIA; PATIENT MONITORING; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SEIZURE; SENSORIMOTOR NEUROPATHY; SENSORY DYSFUNCTION; SIDE EFFECT; STIFF MAN SYNDROME; STRABISMUS; STROKE; SYNCOPE; TINNITUS; VISUAL DISORDER; VOMITING;

ACITRETIN; ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; CREATINE KINASE; DERMATOLOGIC AGENTS; DRUG MONITORING; EXERCISE; HUMANS; HYPERVITAMINOSIS A; ISOTRETINOIN; NEUROMUSCULAR DISEASES; PRACTICE GUIDELINES AS TOPIC; SKIN DISEASES;

EID: 72049106099     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11319020-000000000-00000     Document Type: Review

References (68)

1. Tsambaos D. Retinoids: a new chapter in dermatotherapy. Derm Beruf Umwelt 1996; 44: 182-183
2. Ruzicka T, Larsen FG, Galewicz D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol 2004; 140: 1453-1459
3. Zhang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther 2006 Sep-Oct; 19 (5): 264-271 (Pubitemid 44470110)
4. McNamara IR, Muir J, Galbraith AJ. Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant 2002 Nov; 21 (11): 1201-1205
5. Jones E, Korzenko A, Kriegel D. Oral isotretinoin in the treatment and prevention of cutaneous squamous cell carcinoma. J Drugs Dermatol 2004 Sep-Oct; 3 (5): 498-502
6. Kuan YZ, Hsu HC, Kuo TT, et al. Multiple verrucous carcinomas treated with acitretin. J Am Acad Dermatol 2007 Feb; 56 Suppl. 2: S29-32
7. Eichele G. Retinoids: from hindbrain patterning to Parkinson disease. Trends Genet 1997 Sep; 13 (9): 343-345
8. Zetterstrom RH, Lindqvist E, Mataq de Urquiza A, et al. Role of retinoids in the CNS: differential expression of re-tinoid binding proteins and receptors and evidence for presence of retinoic acid. Eur J Neurosci 1999 Feb; 11 (2): 407-416
9. Maden M. Role and distribution of retinoic acid during CNS development. Int Rev Cytol 2001; 209: 1-77
10. Schneider RA, Hu D, Rubenstein JL, et al. Local retinoid signaling coordinates forebrain and facial morphogenesis by maintaining FGF8 and SHH. Development 2001 Jul; 128(14): 2755-2767
11. Xiao Y, Grieshammer U, Rosenthal N. Regulation of a muscle transgene by retinoic acid. J Cell Biol 1995 Jun; 129 (5): 1345-1354
12. Park JS, Kim S, Han DK, et al. Isolation of neural precursor cells from skeletal muscle tissues and their differentiation into neuron-like cells. Exp Mol Med 2007 Aug; 39 (4): 483-490
13. Amengual J, Ribot J, Bonet ML, et al. Retinoic acid treatment increases lipid oxidation capacity in skeletal muscle of mice. Obesity 2008 Mar; 16 (3): 585-591
14. Invernici G, Cristini S, Madeddu P, et al. Human adult skeletal muscle cells differentiate into cardiomyocyte phe-notype in vitro. Exp Cell Res 2008 Jan 15; 314 (2): 366-376
15. Silverman AK, Ellis CN, Voorhees JJ. Hypervitaminosis A syndrome: a paradigm of retinoid side effects. J Am Acad Dermatol 1987 May; 16 (5 Pt 1): 1027-1039
16. Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol 1992 Dec; 27 (6 Pt 2): S29-33
17. McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol 2001 Nov; 45 (5): S188-94
18. Bigby M, Stern RS. Adverse reactions to isotretinoin. J Am Acad Dermatol 1988 Mar; 18 (3): 543-552
19. Orion E, Matz H, Wolf R. The life-threatening complications of dermatologic therapies. Clin Dermatol 2005 Mar-Apr; 23 (2): 182-192
20. Roytman M, Frumkin A, Bohn TG. Pseudotumor cerebri caused by isotretinoin. Cutis 1988 Nov; 42 (5): 399-400
21. Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis 1995 Mar; 55 (3): 165-168
22. Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol 2003 Aug; 49 (2): 171-182
23. Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-associated intracranial hypertension. Ophthalmology 2004 Jun; 111 (6): 1248-1250
24. Fraunfelder FW, Fraunfelder FT. Evidence for probable causal relationship between tretinoin, acitretin and etreti-nate and intracranial hypertension. J Neuroophthalmol 2004 Sep; 24 (3): 214-216
25. Fishman RA. Polar bear liver, vitamin A, aquaporins, and pseudotumor cerebri. Ann Neurol 2002 Nov; 52 (5): 531-533
26. Masson C, Sztern A. Isotretinoin, a possible cause of epileptic seizures. Presse Med 1991 Dec 21-28; 20 (44): 2264-2265
27. Marroni M, Bellomo G, Bucaneve G, et al. Isotretinoin: possible cause of acute seizure and confusion. Ann Phar-macother 1993 Jun; 27 (6): 793-794
28. Yaman M, Albayram S, Altintas A, et al. A cerebellar demyelinating lesion following treatment of acne with isotretinoin. Clin Exp Dermatol 2008 Mar; 33 (2): 118-121
29. Flachenecker P, Stuke K. National MS registries. J Neurol 2008 Dec; 225 Suppl. 6: 102-108
30. Chroni E, Sakkis TH, Georgiou S, et al. Stiff-person syndrome associated with oral isotretinoin treatment. Neuro-muscul Disord 2002 Nov; 12 (9): 886-888
31. Charalabopoulos K, Papalimneou V, Charalabopoulos A, et al. Two new adverse effects of isotretinoin [letter]. Br J Dermatol 2003 Mar; 148 (3): 593
32. Dalakas MC, Li M, Fujii M, et al. Stiff person syndrome: quantification, specificity and intrathecal synthesis of GAD65 antibodies. Neurology 2001 Sep 11; 57 (5): 780-784
33. Song XQ, Meng F, Ramsey DJ, et al. The GABA rho1 subunit interacts with a cellular retinoic acid binding protein in mammalian retina. Neuroscience 2005; 136 (2): 467-475
34. Skorstad G, Hestvik AL, Torjesen P, et al. GAD65 IgG autoantibodies in stiff person syndrome: clonality, avidity and persistence. Eur J Neurol 2008 Sep; 15 (9): 973-980
35. Nikiforidis G, Tsambaos D, Karamitsos D, et al. Effects of oral isotretinoin on human auditory brainstem response. Dermatology 1994; 189 (1): 62-64
36. Aydoan K, Turan OF, Onart S, et al. Neurological and neurophysiological effects of oral isotretinoin: a prospective investigation using auditory and visual evoked potentials. Eur J Dermatol 2008; 18: 642-646
37. Bremner JD, Fani N, Ashraf A, et al. Functional brain imaging alterations in acne patients treated with iso-tretinoin. Am J Psychiatry 2005 May; 162 (5): 983-991
38. David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol Adverse Drug Exp 1988 Jul-Aug; 3 (4): 273-288
39. Mills CM, Marks R. Adverse reactions to oral retinoids. Drug Saf 1993 Oct; 9 (4): 280-290
40. Starling III J, Koo J. Evidence based or theoretical concern? Pseudotumor cerebri and depression as acitretin side effects. J Drugs Dermatol 2005 Nov-Dec; 4 (6): 690-696
41. Royer B, Ziegler F, Muret P, et al. Acitretin-associated thrombotic stroke. Ann Pharmacother 2002 Dec; 36 (12): 1879-1882
42. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infraction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008 Sep; 159 (4): 895-902
43. Eksioglu E, Oztekin F, Unlu E, et al. Sacroiliitis and polyneuropathy during isotretinoin treatment. Clin Exp Der-matol 2008 Mar; 33 (2): 122-124
44. Pritchard J, Appleton R, Howard R, et al. Guillain-Barre syndrome seen in users of isotretinoin [letter]. Br Med J 2004 Jun; 328 (7455): 1537
45. van Doorn PA. What's new in Guillain-Barre syndrome in 2007-2008? J Peripher Nerv Syst 2009 Jun; 14 (2): 72-74
46. Chroni E, Pasmatzi E, Monastrili A, et al. Short-term oral isotretinoin therapy does not cause clinical or subclinical peripheral neuropathy. J Dermatolog Treat 2006; 17 (1): 6-8
47. Aydogan K, Karli N. Effects of oral isotretinoin therapy on peripheral nerve functions: a preliminary study. Clin Exp Dermatol 2007 Jan; 32 (1): 81-84
48. Aydogan K, Karli N. Effects of oral isotretinoin therapy on peripheral nerve functions: a preliminary study [reply]. Clin Exp Dermatol 2008; 33: 500-522
49. Chroni E, Georgiou S, Monastirli A, et al. Effects of short-term oral acitretin therapy on peripheral nerve function: a prospective neurological and neurophysiological study. Acta Derm Venereol 2001 Nov-Dec; 81 (6): 423-425
50. Chroni E, Monastirli A, Pasmatzi E, et al. Sensorimotor polyneuropathy after a three-month oral acitretin therapy. Clin Neuropharmacol 2002 Nov-Dec; 25 (6): 310-312
51. Tsambaos D, Sakkis T, Chroni E, et al. Peripheral sensory neuropathy associated with short-term oral acitretin therapy. Skin Pharmacol Appl Skin Physiol 2003 Jan-Feb; 16 (1): 46-49
52. Fraunfelder ET, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol 2001 Sep; 132 (3): 299-305
53. Arnault J-P, Petitpain N, Granel-Brocard F, et al. Acitretin and sixth nerve palsy. J Eur Acad Dermatol Venereol 2007 Oct; 21 (9): 1258-1259
54. Rush JA, Younge BR. Paralysis of cranial nerves III, IV, and VI: cause and prognosis in 1000 cases. Arch Ophthal-mol 1981 Jan; 99 (1): 76-79
55. Dicken CH. Retinoids: a review. J Am Acad Dermatol 1984 Oct; 11 (4 pt 1): 541-552
56. Heudes AM, Laroche L. Muscular damage during iso-tretinoin treatment [in French]. Ann Dermatol Venereol 1998 Feb; 125 (2): 94-97
57. Shalita AR, Cunningham WJ, Leyden JJ, et al. Isotretinoin treatment of acne and related disorders: an update. J Am Acad Dermatol 1983 Oct; 9 (4): 629-638
58. Hodak E, Gadoth N, David M, et al. Muscle damage induced by isotretinoin. Br Med J 1986 Aug 16; 293 (6544): 425-426
59. Fiallo P, Tagliapietra A-G. Severe acute myopathy induced by isotretinoin. Arch Dermatol 1996 Dec; 132 (12): 1521-1522
60. Landau M, Mesterman R, Ophir J, et al. Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol 2001 Oct-Nov; 81 (5): 350-352
61. Kaymak Y. Creatine phosphokinase values during iso-tretinoin treatment for acne. Int J Dermatol 2008 Apr; 47 (4): 398-401
62. Trauner MA, Ruben BS. Isotretinoin-induced rhabdomyolysis? A case report. Dermatol Online J 1999; 5: 2
63. Guttman-Yassky E, Hayek T, Muchnik L, et al. Acute rhabdomyolysis and myoglobinuria associated with iso-tretinoin treatment. Int J Dermatol 2003 Jun; 42 (6): 499-500
64. Tillman DM, White SI, Aitchison TC. Isotretinoin, creatine kinase and exercise. Br J Dermatol 1990; 123 Suppl.: 22-23
65. Nieman DC, Dumke CL, Henson DA, et al. Muscle damage is linked to cytokine changes following a 160-km race. Brain Behav Immun 2005 Sep; 19 (5): 398-403
66. Rigobello MP, Scutari G, Friso A, et al. Mitochondrial permeability transition and release of cytochrome c induced by re-tinoid acids. Biochem Pharmacol 1999 Aug 15; 58 (4): 665-670
67. DiMauro S. Mitochondrial myopathies. Curr Opin Rheumatol 2006 Nov; 18 (6): 636-641
68. Lister RK, Lecky BRF, Lewis-Jones MS, et al. Acitretin-induced myopathy. Br J Dermatol 1996; 134: 989-990